This study demonstrated that LCN2 level was correlated with the severity of liver inflammation and the stage of hepatic fibrosis, making it a good candidate biomarker or even a therapeutic target for NAFLD and fibrosis [45, 46]. The gene discussed is LCN2; the disease is metabolic dysfunction-associated steatotic liver disease.